Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Alzheimer disease in 2016

Putting AD treatments and biomarkers to the test

Nature Reviews Neurology volume 13, pages 74–76 (2017)Cite this article

Subjects

Investigational treatments to impede the progression of Alzheimer disease (AD) are being evaluated in clinical trials, and biomarkers to detect and track the disease are being developed and deployed. Recent findings underscore the importance of ongoing clinical trials and biomarker developments in the understanding, treatment and prevention of AD.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Selkoe, D. J. & Hardy, J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol. Med. 8, 595–608 (2016).

    Article  CAS  Google Scholar 

  2. Cummings, J., Morstorf, T. & Lee, G. Alzheimer's drug-development pipeline: 2016. Alzheimers Dement. (NY) 2, 222–232 (2016).

    Google Scholar 

  3. Reiman, E. M. et al. CAP — advancing the evaluation of preclinical Alzheimer disease treatments. Nat. Rev. Neurol. 12, 56–61 (2016).

    Article  CAS  Google Scholar 

  4. Sevigny, J. et al. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature 537, 50–66 (2016).

    Article  CAS  Google Scholar 

  5. Reiman, E. M. Alzheimer's disease: attack on amyloid-β protein. Nature 537, 36–37 (2016).

    Article  CAS  Google Scholar 

  6. Honig, L. S. et al. EXPEDITION 3: a phase 3 trial of solanezumab in mild dementia due to Alzheimer's disease. CTAD http://www.ctad-alzheimer.com/live-expedition-3-webcast (2016).

  7. Schöll, M. et al. PET imaging of tau deposition in the aging human brain. Neuron 89, 971–982 (2016).

    Article  Google Scholar 

  8. Bittner, T. et al. Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid (1–42) in human cerebrospinal fluid. Alzheimers Dement. 12, 517–526 (2016).

    Article  Google Scholar 

  9. Bacioglu, M. et al. Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases. Neuron 91, 56–66 (2016).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

E.M.R. is supported by National Institute on Aging grants RF1 AG041705, UF1 AG046150, R01 AG031581 and P30 AG19610.

Author information

Authors and Affiliations

  1. Eric M. Reiman is at the Banner Alzheimer's Institute, 901 E. Willetta Street, Phoenix, Arizona 85006, USA.,

    Eric M. Reiman

Authors
  1. Eric M. Reiman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eric M. Reiman.

Ethics declarations

Competing interests

E.M.R. is a scientific adviser to Alkahest, Alzheon, Biogen, CereSpir, Denali and Pfizer. He and his parent organization have received research grants from Genentech/Roche, Novartis/Amgen, and Avid/Lilly. He is the inventor of a patent, entitled “Accelerated evaluation of treatments to prevent clinical onset of Alzheimer's disease.”

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Reiman, E. Putting AD treatments and biomarkers to the test. Nat Rev Neurol 13, 74–76 (2017). https://doi.org/10.1038/nrneurol.2017.1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2017.1

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research